- Have any questions?
- 085913 90567
- drgeorgechestdiseases@gmail.com
Lung Cancer Survival Rates by Stage
Thoracic vs Cardiac Surgery: Key Differences?
May 14, 2026
VATS Surgery Recovery Time
June 8, 2026
Survival rates in lung cancer are determined almost entirely by how early the disease is caught. Stage 1 patients who undergo surgery at a dedicated thoracic centre have five-year survival rates exceeding 84 percent in several large published series. Stage 4 patients face a five-year survival rate closer to 2 percent. That gap is not inevitable. It is the direct result of when the diagnosis happens and what follows.
According to Dr. George Karimundackal, a leading Thoracic Surgeon in Mumbai,
“The stage number tells you where the cancer is. What it does not tell you is that the same Stage 3 patient treated at a thoracic-only centre with proper tumour board review gets a genuinely different outcome than one managed elsewhere. Stage is a starting point, not a verdict.”
Lung Cancer Survival Rates by Stage at a Glance
|
Stage |
5-Year Survival Rate |
Typical Treatment |
|
Stage IA |
84 to 95% |
Surgery (VATS or robotic) |
|
Stage IB |
68 to 74% |
Surgery with or without adjuvant therapy |
|
Stage II |
26 to 53% |
Surgery plus chemotherapy |
|
Stage III |
8 to 22% |
Combined modality or surgery in selected cases |
|
Stage IV |
2 to 7% |
Systemic therapy, targeted agents, immunotherapy |
What Determines Survival at Each Stage of Lung Cancer?
Survival figures are averages pulled from large populations. Several specific factors push individual outcomes higher or lower within any given stage.
- Stage at diagnosis: Stage IA1 patients at high-volume centres consistently show five-year survival above 90 percent. Stage IB drops toward 68 to 74 percent, and each substage carries a meaningfully different prognosis.
- Surgical approach and volume: Lung resections done by thoracic-only surgeons at specialist centres carry significantly lower mortality. Minimally invasive lung cancer treatment via VATS or robotic platforms adds faster recovery on top of equivalent oncological outcomes.
- Histological subtype: NSCLC at a localised stage carries a five-year survival rate of around 67 percent. Small cell lung cancer sits far lower at the same stage because it spreads earlier and more aggressively.
- Molecular profile: EGFR mutations, ALK rearrangements, and PD-L1 expression levels now directly change treatment selection and survival at Stage 3 and 4. A patient with a targetable mutation has a meaningfully different trajectory than one without.
Stage numbers are a starting point. What determines individual outcome is the quality of the workup, the surgical approach chosen, and where the treatment happens.
What Do Survival Rates Actually Mean for a Patient?
Statistics describe populations. They do not describe individuals. This is where most families get stuck trying to interpret numbers they find online.
- Rates are historical: Published five-year figures are built on patients diagnosed years before current targeted therapies and immunotherapy combinations became standard. Outcomes for patients treated now are generally better.
- Stage 3 is not a single situation: Stage 3A and Stage 3B are very different clinical realities. Selected Stage 3A patients who respond to neoadjuvant chemotherapy and proceed to resection can achieve survival closer to Stage 2.
- Early detection changes the equation: Only about 16 percent of lung cancer patients are diagnosed at a localised stage. Low-dose CT screening in high-risk individuals is what shifts detection earlier and genuinely moves survival numbers upward.
- Treatment centre matters: Volume, multidisciplinary tumour board structure, robotic and VATS capability, and thoracic anaesthesia experience all produce measurable differences in outcome at every stage.
The clearest thing the data shows is that the earlier the diagnosis and the more specialist the centre, the better the result. Read more about lung cancer symptoms to understand when to act.
Why Choose Dr. George Karimundackal?
Dr. George Karimundackal, MBBS, MS (General Surgery), MCh (Surgical Oncology), MRCS Edinburgh, is Director of Thoracic Surgery at Nanavati Max Super Speciality Hospital, Mumbai. With over 15 years as a thoracic surgeon, he has performed more than 1,000 thoracoscopic procedures and was previously Professor of Thoracic Surgery at Tata Memorial Hospital. Every lung cancer case is reviewed through a structured multidisciplinary tumour board before any surgical decision is made. Patients receive a clear, stage-specific treatment plan from the first consultation.
Frequently Asked Questions
Stage 1 lung cancer has the best outcomes. Five-year survival rates for Stage IA patients can reach 84 to 95 percent depending on the substage, provided surgery is performed at a high-volume thoracic centre.
Stage 3 lung cancer is not routinely curable but selected Stage 3A patients who respond to neoadjuvant chemotherapy and undergo surgery at a specialist centre can achieve long-term survival.
Yes. Non-small cell lung cancer generally has better survival rates than small cell lung cancer at every stage. NSCLC at a localised stage carries a five-year survival rate of around 67 percent versus significantly lower rates for SCLC.
Surgery remains the only reliable method to cure early-stage lung cancer. When performed at a dedicated thoracic centre by a lung cancer specialist, it offers the best chance of long-term survival at Stages 1 and 2.